Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - October 2014

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Capecitabine - Tablets
Fluconazole - Tablets and Powder for Oral Suspension
Romidepsin - lyophilized powder
Anagrelide - Capsules
Asenapine - Sublingual Tablets
Bortezomib - for Injection
Canakinumab
Caspofungin - Injection 
Ciclesonide - Nasal Aerosol
Docetaxel - Injection
Duloxetine - Capsules
Goserelin - Implant
Leuprolide - for Injectable Suspension
Levetiracetam - Injection
Lincomycin - Injection, USP Sterile Solution
Minocycline - for Injection Intravenous
Rabeprazole - Delayed-Release Tablets
Spironolactone - Tablets
Tamsulosin - Capsules
Teriflunomide
Topiramate - Sprinkle Capsules
Varenicline - Tablets 
Zolpidem

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes

Drugs A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Complete Hypertension Guide: Control, Causes and Prevention.
Stay Connected
Available on the Android Market Available on the App Store

Home

Consult

e-Book

Articles

News

Calculators

Drugs

Directories

Education

Consumer

Professional